Skip to main content
TiGenix purchased by Takeda for $622.5M
1/8/2018

TiGenix was acquired by Takeda Pharmaceutical for approximately $622.5 million. Takeda anticipates approval from the European Medicines Agency for TiGenix's Crohn's disease cell therapy Alofisel, or darvadstrocel, this year.

Full Story: